CymaBay Therapeutics, Inc. (CBAY) Financials
CBAY Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 434.7 million | 142.4 million |
2023-09-30 | 451.0 million | 124.9 million |
2023-06-30 | 226.7 million | 118.2 million |
2023-03-31 | 245.3 million | 141.1 million |
CBAY Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -27.6 million | 4.7 million |
2023-09-30 | -26.1 million | 3.7 million |
2023-06-30 | -25.5 million | 3.4 million |
2023-03-31 | 6.2 million | 3.5 million |
CBAY Net Income
No data available :(
CBAY Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 394.3 million | - | 5.3 million |
2023-09-30 | 438.8 million | - | 206000 |
2023-06-30 | 213.8 million | - | 374000 |
2023-03-31 | 236.4 million | - | 537000 |
CBAY Shares Outstanding
CBAY Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 180000 | 22.7 million | 19.8 million | - |
2023-09-30 | - | 20.0 million | 12.2 million | - |
2023-06-30 | 70000 | 19.5 million | 11.6 million | - |
2023-03-31 | 195000 | 18.6 million | 8.3 million | - |
CBAY Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 57000 | 56000 |
2023-09-30 | - | 215000 |
2023-06-30 | 31.0 million | 211000 |
2023-03-31 | - | 199000 |
CBAY
Price: $32.48
52 week price:
Earnings Per Share: -0.93 USD
P/E Ratio: -34.58
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 528000
Ebitda: -8.0 millionMarket Capitalization: 3.7 billion